Interpretation of Expert consensus on treatment and management of tuberculosis-diabetes mellitus comorbidity

doi:10.3969/j.issn.1000-6621.2021.04.004

Abstract

Abstract:

The comorbidity of tuberculosis (TB) and diabetes (DM) is becoming a big clinical challenge. It requires physicians from TB and DM teams to work together to decide treatment plans and conduct follow-up management in order to further increase cure rate and reduce mortality. The Expert consensus on treatment and management of tuberculosis-diabetes mellitus comorbidity was published on the first issue of 2021 in the Chinese Journal of Antituberculosis. This consensus offered management recommendations for frequently met problems during the treatment of TB-DM. We hereby further interpret the concept of TB-DM comorbidity, the management of diabetes, adverse drug reactions and precautions during treatment for clinicians in our country when taking care of patients with TB-DM.

Key words: Tuberculosis, Diabetes mellitus, Combined modality therapy, Practice management, medical, Drug therapy, combination, Consensus development conferences as topic, Comment, problembased learning

DENG Guo-fang. Interpretation of Expert consensus on treatment and management of tuberculosis-diabetes mellitus comorbidity[J]. Chinese Journal of Antituberculosis, 2021, 43(4): 318-321. doi: 10.3969/j.issn.1000-6621.2021.04.004

Figures/Tables 2

References 17

[1]	Noubiap JJ, Nansseu JR, Nyaga UF, et al. Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2.3 million patients with tuberculosis. Lancet Glob Health, 2019,7(4):e448-e460. doi: 10.1016/S2214-109X(18)30487-X. doi: 10.1016/S2214-109X(18)30487-X URL pmid: 30819531
[2]	国家感染性疾病临床医学研究中心, 深圳市第三人民医院, 国家代谢性疾病临床医学研究中心, 等. 结核病与糖尿病共病的治疗管理专家共识. 中国防痨杂志, 2021,43(1):12-22. doi: 10.3969/j.issn.1000-6621.2021.01.004.
[3]	Kernick D, Chew-Graham CA, O’Flynn N. Clinical assessment and management of multimorbidity: NICE guideline. Br J Gen Pract, 2017,67(658):235-236. doi: 10.3399/bjgp17X690857. doi: 10.3399/bjgp17X690857 URL pmid: 28450343
[4]	颜俊娴, 路云. 英国共病管理政策对我国的启示. 现代商贸工业, 2018,6:66-68. doi: 10.19311/j.cnki.1672-3198.2018.06.028.
[5]	Baker MA, Harries AD, Jeon CY, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med, 2011,9:81. doi: 10.1186/1741-7015-9-81. doi: 10.1186/1741-7015-9-81 URL pmid: 21722362
[6]	Lin Y, Harries AD, Kumar AM, et al. Management of diabetes mellitus-tuberculosis: a guide to the essential practice. Paris: International Union Against Tuberculosis and Lung Disease, 2019.
[7]	Harries AD, Kumar AM, Satyanarayana S, et al. Diabetes mellitus and tuberculosis: programmatic management issues. Int J Tuberc Lung Dis, 2015,19(8):879-886. doi: 10.5588/ijtld.15.0069. doi: 10.5588/ijtld.15.0069 URL pmid: 26162352
[8]	Lin Y, Yuan Y, Zhao X, et al. The change in blood glucose levels in tuberculosis patients before and during anti-tuberculosis treatment in China. Glob Health Action, 2017,10(1):1289737.doi: 10.1080/16549716.2017.1289737. doi: 10.1080/16549716.2017.1289737 URL pmid: 28470109
[9]	Lin Y, Li L, Mi F, et al. Screening patients with diabetes mellitus for tuberculosis in China. Trop Med Int Health, 2012,17(10):1302-1308. doi: 10.1111/j.1365-3156.2012.03069.x. doi: 10.1111/j.1365-3156.2012.03069.x URL
[10]	Lin Y, Innes A, Xu L, et al. Screening of patients with diabetes mellitus for tuberculosis in community health settings in China. Trop Med Int Health, 2015,20(8):1073-1080. doi: 10.1111/tmi.12519. doi: 10.1111/tmi.12519 URL pmid: 25877338
[11]	Yoon YS, Jung JW, Jeon EJ, et al. The effect of diabetes control status on treatment response in pulmonary tuberculosis: a prospective study. Thorax, 2017,72(3):263-270. doi: 10.1136/thoraxjnl-2015-207686. doi: 10.1136/thoraxjnl-2015-207686 URL pmid: 27553224
[12]	中国医师协会内分泌代谢科医师分会, 中国住院患者血糖管理专家组. 中国住院患者血糖管理专家共识. 中华内分泌代谢杂志, 2017,33(1):1-10. doi: 10.3760.j.issn.1000-6699.2017.01.001.
[13]	Lin KH, Luo CW, Chen SP, et al. α-Glucosidase Inhibitor Can Effectively Inhibit the Risk of Tuberculosis in Patients with Diabetes: A Nested Case-Control Study. Biomed Res Int, 2020,2020:8085106. doi: 10.1155/2020/8085106. doi: 10.1155/2020/8085106 URL pmid: 32509871
[14]	Wang JY, Lee MC, Shu CC, et al. Optimal duration of anti-TB treatment in patients with diabetes: nine or six months. Chest, 2015,147(2):520-528. doi: 10.1378/chest.14-0918. doi: 10.1378/chest.14-0918 URL pmid: 25255302
[15]	Chang JT, Dou HY, Yen CL, et al. Effect of type 2 diabetes mellitus on the clinical severity and treatment outcome in patients with pulmonary tuberculosis: a potential role in the emergence of multidrug-resistance. J Formos Med Assoc, 2011,110(6):372-381. doi: 10.1016/S0929-6646(11)60055-7.
[16]	Atif M, Sulaiman SA, Shafie AA, et al. Duration of treatment in pulmonary tuberculosis: are international guidelines on the management of tuberculosis missing something. Public Health, 2015,129(6):777782. doi: 10.1016/j.puhe.2015.04.010.
[17]	Wu Z, Guo J, Huang Y, et al. Diabetes mellitus in patients with pulmonary tuberculosis in an aging population in Shanghai, China: Prevalence, clinical characteristics and outcomes. J Diabetes Complications, 2016,30(2):237-241. doi: 10.1016/j.jdiacomp.2015.11.014. doi: 10.1016/j.jdiacomp.2015.11.014 URL pmid: 26684166

临床类别	血糖控制目标
结核病治疗期间^{[6, 12]}
年龄较轻、病程较短、预期寿命较长、无并发症、未并发心血管疾病	HbA1c<7.0%,空腹<7.0mmol/L,非空腹<10.0mmol/L
并发心脑血管疾病、心脑血管疾病高风险、高龄、结核病病情严重	HbA1c<8.0%,空腹7.8~10.0mmol/L,非空腹 7.8~13.9mmol/L
非结核病治疗期间^[12,13]
年龄较轻、病程较短、预期寿命较长、无并发症、未并发心血管疾病	HbA1c<6.5%,空腹4.4~6.1mmol/L,非空腹 6.1~7.8mmol/L
大多数非妊娠成年2型糖尿病患者	HbA1c<7.0%,空腹 4.4~7.0mmol/L,非空腹<10.0mmol/L
高龄、低血糖发生风险较高且无法耐受低血糖、存在多器官功能不全、预期生存期低于5年、需重症监护	HbA1c<8.0%,空腹7.8~10.0mmol/L,非空腹 7.8~13.9mmol/L